Genialis’ Chief Discovery Officer, Luka Ausec, recently joined Tjaša Zajc on the Faces of Digital Health Podcast to discuss some of the most pressing challenges and innovations in cancer research and drug development. Their conversation covered the role of AI in precision medicine, the limitations of current biomarker research, and the ethical dilemmas in healthcare resource allocation.
The role of synthetic data in cancer research
A key topic in the discussion was the power of synthetic data.
As Luka put it, “Synthetic data could revolutionize research by bypassing privacy barriers and enabling broader access to patient insights.”
This approach allows researchers to model disease progression, test new therapies, and refine AI-driven predictions without relying solely on limited real-world patient data.
Beyond AI, the conversation also touched on the role of environmental and lifestyle factors in treatment outcomes, the regulatory hurdles in AI-driven drug development, and the balance between medical advancements and sustainable healthcare spending.
Tune in to the full discussion
Listen to the full episode to gain deeper insights into:
- How AI and machine learning are reshaping precision medicine
- The need for more complex and predictive biomarker models
- The impact of diet and environmental factors on cancer treatment
- The future of synthetic data and digital twins in research
- Ethical and economic challenges in oncology drug development
Watch or listen here: Apple podcasts | Spotify
